ITCI News and Press, Intra-Cellular Therapies Inc. From 03/28/23

2023-03-28 10:00:38 ET Gainers: Biomea Fusion ( BMEA ) +56% . Oscar Health ( OSCR ) +54% . Viking Therapeutics ( VKTX ) +51% . Intra-Cellular Therapies ( ITCI ) +20% . Guardion Health Sciences ( GHSI ) +17% . Losers...

2023-03-28 08:43:59 ET Intra-Cellular Therapies ( NASDAQ: ITCI ) added ~14% on Tuesday in the pre-market trading after announcing that its depression candidate lumateperone reached the key goals in a trial for patients with depressive episodes. Study 403 was a randomized...

Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the Montgomery Asberg Depression Rating Scale (MADRS) for each patient population including: -combined major depressive disorder (MDD) with mixed features and bipolar depression with mixed fe...

2023-03-05 21:14:52 ET Summary Intra-Cellular Therapies develops small-molecule drugs targeting the central nervous system for neuropsychiatric and neurological disorders. Caplyta is their lead drug, approved by the FDA for schizophrenia and bipolar depression. Caplyta's exception...

Intra-Cellular Therapies, Inc. (ITCI) Q4 2022 Earnings Conference Call March 01, 2023 08:30 A.M. ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman, and CEO Mark Neumann - EVP & Chief Commercial Officer ...

Intra-Cellular Therapies press release ( NASDAQ: ITCI ): Q4 GAAP EPS of -$0.45 beats by $0.15 . Revenue of $87.87M (+242.3% Y/Y) beats by $0.9M . CEO comment: "We expect 2023 to be another year of significant growth for CAPLYTA and the company.” CAPLYTA 2023...

Full year 2022 total revenues of $250.3 million, compared to $83.8 million in 2021 CAPLYTA fourth quarter 2022 net product sales grew to $87.4 million, a 243% increase over the same period in 2021 and a 22% sequential increase over the third quarter 2022 Full year 2022 CAPL...

Intra-Cellular Therapies ( NASDAQ: ITCI ) is scheduled to announce Q4 earnings results on Wednesday, March 1st, before market open. The consensus EPS Estimate is -$0.59 (+43.8% Y/Y) and the consensus Revenue Estimate is $86.97M (+238.8% Y/Y). Over the last 1 year, ITCI has b...

Major earning expected before the bell on Wednesday include: Amarin ( AMRN ) Lowe's Companies ( LOW ) NIO ( NIO ) Royal Bank of Canada ( RY ) Workhorse Group ( WKHS ) For further details see: Notable earnings before Wednesday's open

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast ...